El SalvadorTuberculosis profile
Population  2015 6.1 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.12 (0.085–0.15) 1.9 (1.4–2.5)
Mortality (HIV+TB only) 0.024 (<0.01–0.12) 0.39 (0–1.9)
Incidence  (includes HIV+TB) 2.7 (2.4–2.9) 43 (40–47)
Incidence (HIV+TB only) 0.21 (0.19–0.23) 3.5 (3.2–3.8)
Incidence (MDR/RR-TB)** 0.04 (0.014–0.067) 0.65 (0.23–1.1)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.15 (0.11–0.2) 0.74 (0.5–0.98) 0.89 (0.61–1.2)
Males 0.12 (0.089–0.16) 1.6 (1.3–2) 1.8 (1.4–2.1)
Total 0.28 (0.22–0.33) 2.4 (2.3–2.5) 2.7 (2.4–2.9)
TB case notifications, 2015  
Total cases notified 2 461
Total new and relapse 2 452
          - % tested with rapid diagnostics at time of diagnosis 15%
          - % with known HIV status 97%
          - % pulmonary 86%
          - % bacteriologically confirmed among pulmonary 90%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 92% (85–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.05 (0.03–0.08)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 182 8%
          - on antiretroviral therapy 152 84%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  30
(10–50)
Estimated % of TB cases with MDR/RR-TB 1.1% (0.17–2.1) 4.1% (1.3–9.2)  
% notified tested for rifampicin resistance 49% 47% 1 194
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 25, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 22, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 91% 2 206
Previously treated cases, excluding relapse, registered in 2014 43% 14
HIV-positive TB cases, all types, registered in 2014 75% 203
MDR/RR-TB cases started on second-line treatment in 2013 90% 10
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 39%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) 5.8
Funding source: 29% domestic, 71% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-08 Data: www.who.int/tb/data